SRT Sartorius AG

EQS-News: SARTORIUS AG: Resolutions of the Annual General Meeting of Sartorius AG

EQS-News: SARTORIUS AG / Key word(s): AGM/EGM
SARTORIUS AG: Resolutions of the Annual General Meeting of Sartorius AG

29.03.2023 / 17:04 CET/CEST
The issuer is solely responsible for the content of this announcement.


Göttingen, March 29, 2023

Resolutions of the Annual General Meeting of Sartorius AG

At today’s virtual Annual General Meeting, the shareholders of Sartorius AG approved the proposals of the Executive Board and the Supervisory Board by a large majority, including the proposal to distribute a dividend of 1.44 euros per preference share and 1.43 euros per ordinary share. The total amount disbursed will be 98.2 million euros. In the previous year, dividends were 1.26euros per preference share and 1.25 euros per ordinary share.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events.


Further information




Financial calendar
April 20, 2023: Publication of first-quarter figures (January to March 2023)
July 21, 2023: Publication of first-half figures (January to June 2023)
October 19, 2023: Publication of nine-month figures (January to September 2023)


A profile of Sartorius
The Sartorius Group is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications and vaccines safely, rapidly and economically. The company based in Goettingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius delivers significant organic growth and regularly expands its portfolio through the acquisition of complementary technologies. In fiscal 2022, the company generated sales revenue of around 4.2 billion euros. At the end of 2022, around 16,000 employees were working for customers around the globe.


Contact
Timo Lindemann
Corporate Communications
+49 (0)551 308 4724


Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.


29.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail:
Internet:
ISIN: DE0007165607, DE0007165631
WKN: 716560 , 716563
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1589605

 
End of News EQS News Service

1589605  29.03.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1589605&application_name=news&site_id=research_pool
EN
29/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sartorius AG

Sartorius: 1 director

A director at Sartorius bought 400 shares at 173.350EUR and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

Thomas J. Schiessle
  • Thomas J. Schiessle

CEO verlängert nicht über Nov. 2025 hinaus - Q1/24 dokumentierte opera...

Nach knapp 20 Jahren als hat CEO Dr. Joachim Kreuzburg angekündigt – aus Gründen der persönlichen Lebensplanung - keine nochmalige Vertrags­verlängerung - über den 30.11.25 hinaus – anzustreben; er strebe ferner keine operative Position in einem anderen Unternehmen an. Die Ankeraktionäre werden nun wichtig: Seit in 2023 ist Bio-Rad Laboratories Inc. Aktionär (derzeit Anteil an  Ord. 28%; Pref: 38%). Durch Lothar Kappich (SRT-AR-Vorsitz) wird die Horst Sartorius Erbengemeinschaft in Höhe von 50,0...

Thomas J. Schiessle
  • Thomas J. Schiessle

CEO will not extend beyond Nov. 2025 - Q1/24 documented operational tu...

After almost 20 years as CEO, Dr Joachim Kreuzburg has announced - for reasons of personal life planning - that he will not seek a further contract extension beyond 30.11.2025; furthermore, he will not seek an operational position in another company. The anchor shareholders are now becoming important: Bio-Rad Laboratories Inc. has been a shareholder since 2023 (current share in Ord. 28%; Pref: 38%). Lothar Kappich (SRT-SB-Chairman) represents the Horst Sartorius community of heirs in the amount ...

 PRESS RELEASE

EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuz...

EQS-News: SARTORIUS AG / Key word(s): Personnel Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret (news with additional features) 02.07.2024 / 10:53 CET/CEST The issuer is solely responsible for the content of this announcement.   Göttingen, July 2, 2024 Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret The long-standing CEO of Sartorius AG, Dr. Joachim Kreuzburg, has informed the ...

 PRESS RELEASE

EQS-News: Sartorius AG: Joachim Kreuzburg strebt nach mehr als 20 Jahr...

EQS-News: SARTORIUS AG / Schlagwort(e): Personalie Sartorius AG: Joachim Kreuzburg strebt nach mehr als 20 Jahren als Vorstandsvorsitzender keine weitere Amtszeit an – Aufsichtsrat äußert großes Bedauern (News mit Zusatzmaterial) 02.07.2024 / 10:53 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Göttingen, 2. Juli 2024 Sartorius AG: Joachim Kreuzburg strebt nach mehr als 20 Jahren als Vorstandsvorsitzender keine weitere Amtszeit an – Aufsichtsrat äußert großes Bedauern Der langjährige Vorstandsvorsitzende der Sartorius AG, Dr. Joachim ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch